Most frequently, the 3p arm was co-deleted in 85%-100% samples with TREX1 loss in 19 tumor types including adrenocortical carcinoma (ACC), breast (BRCA), cervical (ESCA), head and neck (HNSC), pancreatic (PAAD), and thyroid (THCA) carcinomas, kidney cancers (KICH, KIRC, and KIRP), non-small cell lung cancer (LUAD and LUSC), pheochromocytoma and paraganglioma (PCPG), testicular germ cell tumors (TGCT) and uveal melanoma (UVM). Here, TREX1 is linked to thyroid gland disorder.